/PRNewswire/ Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of.
Full IDE Data Set Demonstrates Statistically Significant Reduction of All-Cause Mortality and Primary Major Adverse Events at 30 days with use of AMDS in Acute DeBakey Type I Dissections.
Artivion (AORT) Announces Presentation of Late-Breaking Interim Data from AMDS PERSEVERE Trial streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Interim Data Demonstrate Meaningful Reduction of All-Cause Mortality with AMDS
ATLANTA, Oct. 5, 2023 /PRNewswire/ Artivion, Inc. , a leading cardiac and vascular surgery company focused on aortic.
/PRNewswire/ Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today presented interim results from the.